drug
asciminib hydrochloride
Marketedupdated 3mo agoby $NVS NOVARTIS AG
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7- drugSCEMBLIX46 co-mentions · 13 sources
- tagApproval44 co-mentions · 11 sources
- tagSmall Molecule22 co-mentions · 11 sources
- tagOncology3 co-mentions · 2 sources
- company$NVSNOVARTIS AG1 co-mentions · 1 sources
- company$NVSEFNOVARTIS AG1 co-mentions · 1 sources
- companyWashington University School of Medicine1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for blast phase chronic myelogenous leukemia, bcr-abl1 positive and chronic myelogenous leukemia.
all catalysts(13)
approval · 11
Oct 29, 2021
approval
$NVS150.88-0.55%
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 29, 2021
approval
$NVS150.88-0.55%
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 12, 2022
approval
$NVS150.88-0.55%
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Jun 26, 2023
approval
$NVS150.88-0.55%
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Nov 8, 2023
approval
$NVS150.88-0.55%
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Jun 18, 2024
approval
$NVS150.88-0.55%
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Aug 7, 2024
approval
$NVS150.88-0.55%
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 29, 2024
approval
$NVS150.88-0.55%
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 29, 2024
approval
$NVS150.88-0.55%
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 2, 2025
approval
$NVS150.88-0.55%
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Nov 25, 2025
approval
$NVS150.88-0.55%
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
phase 0 trial initiation · 1
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 29, 2026
74 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- May 17, 2040method-of-use (U-1374)US 12252479
- May 17, 2040method-of-use (U-1374)US 12252479
- May 17, 2040method-of-use (U-1374)US 12252479
- May 14, 2040compositionUS 11407735
- May 14, 2040compositionUS 11407735
- May 14, 2040compositionUS 11407735
- May 14, 2040formulationUS 12252478
- May 14, 2040formulationUS 12252478
- May 14, 2040formulationUS 12252478
- Oct 29, 2035compositionUS 8829195
- Oct 29, 2035compositionUS 8829195
- Oct 29, 2035compositionUS 8829195
FDA exclusivities (19)
- Oct 29, 2031ODE-499Orphan Drug (7y)
- Oct 29, 2031ODE-499Orphan Drug (7y)
- Oct 29, 2031ODE-500Orphan Drug (7y)
- Oct 29, 2031ODE-500Orphan Drug (7y)
- Oct 29, 2028ODE-382Orphan Drug (7y)2.2y
- Oct 29, 2028ODE-382Orphan Drug (7y)2.2y
- Oct 29, 2028ODE-381Orphan Drug (7y)2.2y
- Oct 29, 2028ODE-381Orphan Drug (7y)2.2y
- Oct 29, 2028ODE*ODE*2.2y
- Oct 2, 2028M-318Method (3y)2.1y
- Oct 2, 2028M-318Method (3y)2.1y
- Oct 2, 2028M-318Method (3y)2.1y
- Oct 29, 2027I-953Indication (3y)1.2y
- Oct 29, 2027I-954Indication (3y)1.2y
- Oct 29, 2027I-954Indication (3y)1.2y
- Oct 29, 2027I-953Indication (3y)1.2y
- Oct 29, 2026NCENew Chemical Entity (5y)74d
- Oct 29, 2026NCENew Chemical Entity (5y)74d
- Oct 29, 2026NCENew Chemical Entity (5y)74d
News(3)
- Novartis climbs on upbeat drug sales as key readouts loomA return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.biopharma_dive · 24d ago
- J&J looks to widen Imaavy’s use; $300M backs rare disease drug launchNew data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.biopharma_dive · 2mo ago
- Merck still sees ‘compelling’ outlook for Terns leukemia drugDespite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.biopharma_dive · 3mo ago
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that